• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Learn Why The Bull Case For Merit Medical Systems Stock Could Change Following Q2 Growth Surge

    Simply Wall St·10/02/2026 16:24:56
    Listen to the news
    • Merit Medical Systems reported about 9% organic constant-currency growth in Q2, its strongest in three years, led by Vascular Intervention, Access, Cardiac Therapies, and Endoscopy. The company maintained guidance for 2026 adjusted EPS of $4.25 to $4.35 and total revenue growth of 8%, despite tariff-related margin pressure.
    • Management highlighted that Q3 is expected to be seasonally softer before a planned Q4 rebound. The oncology portfolio and Endoscopy are viewed as incremental growth levers that could reshape how investors think about the depth of Merit Medical Systems' procedure-driven demand.
    • We will look at how Merit Medical Systems' investment narrative is influenced by this 9% Q2 organic growth and segment performance.

    Scan beyond Merit Medical Systems and compare its momentum with a hand-picked 28 high quality undervalued stocks that also pair procedure-driven demand with strong fundamentals.

    Merit Medical Systems Investment Narrative Recap

    To own Merit Medical Systems, you need to believe that procedure volumes in cardiovascular, oncology, and endoscopy can support steady organic growth while tariffs, reimbursement issues, and China softness stay manageable. The recent 9% organic constant-currency Q2 performance, plus management reaffirming 2026 EPS and revenue growth guidance, points to a business that sees current headwinds as absorbable rather than thesis breaking.

    In the near term, the key swing factor is how Q3 seasonality and the planned Q4 rebound actually play out in margins and cash generation with tariffs pressuring costs. The biggest operational risk remains reimbursement and pricing pressure on premium products like WRAPSODY CIE, particularly after earlier filing errors and ongoing volume-based purchasing in China.

    The most relevant update tied to this Q2 strength is management reiterating its 2026 adjusted EPS outlook of US$4.25 to US$4.35, along with an 8% total revenue growth target. That stance links recent momentum directly to near-term execution goals and gives you a concrete yardstick for judging whether Merit Medical Systems is tracking to its own plan.

    Regarding potential catalysts, the oncology and Endoscopy portfolios sit at the center of that guidance, since they are framed as incremental growth engines on top of the core cardiovascular and Access lines. Any further delay in WRAPSODY reimbursement, tariff escalation, or weaker APAC demand would work against that earnings range, so investors will likely watch pricing, mix, and operating expense discipline very closely across the next few quarters.

    Merit Medical Systems' analyst narrative points to revenues of US$1.9b and earnings of US$226.4 million by 2029, based on 6.3% yearly revenue growth and an earnings increase of about US$80.8 million from US$145.6 million today.

    Uncover how Merit Medical Systems' fair value indicates a 16% potential upside to its current price that may not last much longer.

    NasdaqGS:MMSI 1-Year Stock Price Chart
    NasdaqGS:MMSI 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternative view on Merit Medical Systems focuses less on Q2 strength and more on tariff and freight costs limiting progress. The most cautious analysts were modeling about US$1.9b of 2029 revenue and earnings of roughly US$225.1 million before this update. That is a slower path than consensus. Use this new quarter as a chance to compare those expectations and decide which storyline fits your own outlook.

    Explore another Merit Medical Systems fair value estimate, including one that suggests it could be worth just $100.27.

    Reach Your Own Conclusion

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Merit Medical Systems?

    If Merit Medical Systems has sharpened your focus on procedure-driven businesses, it can help to widen the lens and compare it with other opportunities that balance quality, risk, and income potential. The Simply Wall St Screener gives you a structured way to do that, so you can line up different stocks against the same checklist and see which ones actually fit your criteria rather than just catching your eye on a headline.

    • For investors who want potential growth with a strict filter on quality and valuation, scan a curated set of 19 high quality undiscovered gems that may not yet be heavily followed by the market.
    • If capital preservation and steadier profiles are your priority, narrow your search to a focused 31 resilient stocks with low risk scores that score well on resilience and balance of risk factors.
    • Those building a portfolio around dependable cash flows can zero in on income ideas using a targeted 7 dividend fortresses aiming to pair higher yields with business stability.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.